KR102778218B1 - 심혈관 병태에서의 세마글루타이드 - Google Patents

심혈관 병태에서의 세마글루타이드 Download PDF

Info

Publication number
KR102778218B1
KR102778218B1 KR1020227036550A KR20227036550A KR102778218B1 KR 102778218 B1 KR102778218 B1 KR 102778218B1 KR 1020227036550 A KR1020227036550 A KR 1020227036550A KR 20227036550 A KR20227036550 A KR 20227036550A KR 102778218 B1 KR102778218 B1 KR 102778218B1
Authority
KR
South Korea
Prior art keywords
semaglutide
pharmaceutical composition
mace
subject
fatal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227036550A
Other languages
English (en)
Korean (ko)
Other versions
KR20220147712A (ko
Inventor
올루프 크리스티안 호이베르그 한센
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58668875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102778218(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Priority to KR1020257007151A priority Critical patent/KR20250038818A/ko
Publication of KR20220147712A publication Critical patent/KR20220147712A/ko
Application granted granted Critical
Publication of KR102778218B1 publication Critical patent/KR102778218B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
KR1020227036550A 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드 Active KR102778218B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257007151A KR20250038818A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP16167458 2016-04-28
EP16167458.5 2016-04-28
EP16188262 2016-09-12
EP16188262.6 2016-09-12
PCT/EP2017/060160 WO2017186896A1 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions
KR1020187033310A KR20180135012A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187033310A Division KR20180135012A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257007151A Division KR20250038818A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Publications (2)

Publication Number Publication Date
KR20220147712A KR20220147712A (ko) 2022-11-03
KR102778218B1 true KR102778218B1 (ko) 2025-03-10

Family

ID=58668875

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227036550A Active KR102778218B1 (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드
KR1020187033310A Ceased KR20180135012A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드
KR1020257007151A Pending KR20250038818A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187033310A Ceased KR20180135012A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드
KR1020257007151A Pending KR20250038818A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Country Status (24)

Country Link
US (3) US12569543B2 (https=)
EP (1) EP3448416B1 (https=)
JP (1) JP7221694B2 (https=)
KR (3) KR102778218B1 (https=)
CN (1) CN109069589B (https=)
AU (2) AU2017256774B2 (https=)
BR (1) BR112018072020A2 (https=)
CA (1) CA3022535A1 (https=)
CL (1) CL2018003045A1 (https=)
DK (1) DK3448416T3 (https=)
ES (1) ES2928007T3 (https=)
HR (1) HRP20221150T1 (https=)
HU (1) HUE060040T2 (https=)
IL (1) IL262390B1 (https=)
MA (1) MA44762A (https=)
MX (1) MX2018012700A (https=)
MY (1) MY202967A (https=)
PH (1) PH12018502274B1 (https=)
PL (1) PL3448416T3 (https=)
RS (1) RS63630B1 (https=)
RU (1) RU2768283C2 (https=)
SI (1) SI3448416T1 (https=)
WO (1) WO2017186896A1 (https=)
ZA (2) ZA202507394B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3022535A1 (en) 2016-04-28 2017-11-02 Novo Nordisk A/S Semaglutide in cardiovascular conditions
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
SG11202103137WA (en) * 2018-10-26 2021-04-29 Novo Nordisk As Stable semaglutide compositions and uses thereof
ES2994462T3 (en) * 2018-12-21 2025-01-24 Novo Nordisk As Process of spray drying of glp-1 peptide
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
CN114699510B (zh) * 2021-12-29 2024-07-16 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法
CN119317635A (zh) * 2022-06-08 2025-01-14 载度思生命科学有限公司 用于2型糖尿病和体重管理的可重复使用的多剂量可变剂量的单一笔式注射器
CN117462654A (zh) * 2023-09-28 2024-01-30 武汉大学人民医院（湖北省人民医院） 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015071355A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2003084563A1 (en) 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
NZ598170A (en) 2009-10-02 2014-06-27 Boehringer Ingelheim Int Pharmaceutical compositions comprising bi-1356 and metformin
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) * 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
SI2651398T1 (en) * 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6126097B2 (ja) 2011-09-06 2017-05-10 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6374862B2 (ja) 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
WO2014066992A1 (en) 2012-11-02 2014-05-08 Mansoor Husain Methods for inhibiting platelet aggregation using glp-1 receptor agonists
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
EP3744327A1 (en) 2013-03-15 2020-12-02 Boehringer Ingelheim International GmbH Use of linagliptin in cardio- and renoprotective antidiabetic therapy
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CR20170456A (es) 2015-04-07 2018-06-13 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapias combinadas
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
CA3022535A1 (en) * 2016-04-28 2017-11-02 Novo Nordisk A/S Semaglutide in cardiovascular conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015071355A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof

Also Published As

Publication number Publication date
PH12018502274A1 (en) 2019-09-09
ZA202507394B (en) 2025-09-25
EP3448416B1 (en) 2022-08-10
ZA202507395B (en) 2025-09-25
AU2017256774B2 (en) 2024-07-11
US20250288649A1 (en) 2025-09-18
HUE060040T2 (hu) 2023-01-28
KR20250038818A (ko) 2025-03-19
US12569543B2 (en) 2026-03-10
CA3022535A1 (en) 2017-11-02
WO2017186896A1 (en) 2017-11-02
CN109069589B (zh) 2022-09-06
MX2018012700A (es) 2019-01-30
JP2019514925A (ja) 2019-06-06
PH12018502274B1 (en) 2024-02-28
KR20180135012A (ko) 2018-12-19
CN109069589A (zh) 2018-12-21
AU2017256774A1 (en) 2018-11-01
EP3448416A1 (en) 2019-03-06
RU2768283C2 (ru) 2022-03-23
KR20220147712A (ko) 2022-11-03
IL262390A (en) 2018-12-31
PL3448416T3 (pl) 2022-11-07
IL262390B1 (en) 2023-05-01
US20190134162A1 (en) 2019-05-09
RS63630B1 (sr) 2022-10-31
DK3448416T3 (da) 2022-10-03
RU2018140900A3 (https=) 2020-09-28
AU2024227113A1 (en) 2024-10-31
JP7221694B2 (ja) 2023-02-14
US20250262281A1 (en) 2025-08-21
MA44762A (fr) 2019-03-06
CL2018003045A1 (es) 2018-12-14
SI3448416T1 (sl) 2022-10-28
HRP20221150T1 (hr) 2022-11-25
RU2018140900A (ru) 2020-05-28
BR112018072020A2 (pt) 2019-02-12
ES2928007T3 (es) 2022-11-14
MY202967A (en) 2024-05-31

Similar Documents

Publication Publication Date Title
KR102778218B1 (ko) 심혈관 병태에서의 세마글루타이드
AU2024201937A1 (en) Liraglutide in cardiovascular conditions
CN110022935A (zh) 用于心血管病况的德谷胰岛素
US20200181222A1 (en) Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
HK1261741A1 (en) Semaglutide in cardiovascular conditions
HK1261741B (en) Semaglutide in cardiovascular conditions
US20190091295A1 (en) Liraglutide in Renal Conditions
WO2017149109A1 (en) Liraglutide in diabetic foot ulcer
BR122025010585A2 (pt) Uso de semaglutida para reduzir o risco de um evento cardiovascular adverso maior (mace) em indivíduos com diabetes mellitus tipo 2 e alto risco cardiovascular
HK1259166B (en) Liraglutide in cardiovascular conditions
HK1259166A1 (en) Liraglutide in cardiovascular conditions

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601